Eyenovia has been granted a patent for a method of delivering medicament droplets to the eye surface using a piezoelectric actuated ejection device. The droplets contain specific ophthalmic compositions and are delivered with precise size and velocity parameters to ensure effective treatment. GlobalData’s report on Eyenovia gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Eyenovia Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Eyenovia, Ultrasonic atomizers was a key innovation area identified from patents. Eyenovia's grant share as of January 2024 was 39%. Grant share is based on the ratio of number of grants to total number of patents.

A recently granted patent (Publication Number: US11839487B2) discloses a method for delivering droplets to the surface of an eye using a piezoelectric actuated ejection device. The droplets, containing an ophthalmic composition of tropicamide and phenylephrine hydrochloride, have specific characteristics such as a total volume of 5 µl to 10 µl, an average droplet size from 30 microns to 100 microns, and an average initial ejecting velocity from 1 m/s to about 5 m/s. The device includes a housing, a reservoir with the ophthalmic composition, and an ejector mechanism with a piezoelectric actuator to generate the droplets upon actuation.

Furthermore, the ophthalmic composition in the droplets consists of approximately 2.5% phenylephrine hydrochloride and about 1% tropicamide. The composition may also include a preservative, with a concentration of 0.1% or less. Both the ophthalmic composition and the droplets themselves are in the form of a solution, ensuring effective delivery to the eye's surface. This patented method offers a precise and controlled way of administering ophthalmic medications to patients in need, potentially improving treatment outcomes and patient comfort during the process.

To know more about GlobalData’s detailed insights on Eyenovia, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies